Fig. 1: Study flowchart.
From the starting population (n = 413), 92 patients were excluded. Hence, molecular profiling and survival analyses were performed with 327/413 patients (79.2%).
Fig. 1: Study flowchart. | Blood Cancer Journal
From the starting population (n = 413), 92 patients were excluded. Hence, molecular profiling and survival analyses were performed with 327/413 patients (79.2%).
